KRAS and colorectal carcinoma: Following this assumption, all pancreatic progenitor, ADEX and immunogenic patients could be treated in order to increase intracellular ROS and decrease the levels of antioxidant systems, as previously described with oncogenic KRAS colorectal cancer (CRC) models treated with β-elemene (Pterodon emarginatus) and Cetuximab [105].